Here are what the editors at HealthDay consider to be the most important developments in Gastroenterology for January 2019. This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory changes that are the most likely to affect clinical practice.
Liver Transplant Wait List May Not Prioritize High-Risk Patients
THURSDAY, Jan. 31, 2019 (HealthDay News) — The current method for ranking patients on the liver transplantation wait list may not prioritize some of the sickest candidates, according to a study recently published online in Gastroenterology.
Public Health Interventions Could Cut Global Burden of Hepatitis C
TUESDAY, Jan. 29, 2019 (HealthDay News) — Public health interventions can go a long way toward meeting World Health Organization hepatitis C virus (HCV) targets, according to a study published online Jan. 28 in The Lancet.
New Guidelines Introduced for Inflammatory Bowel Disease in Pregnancy
TUESDAY, Jan. 29, 2019 (HealthDay News) — The American Gastroenterological Association (AGA) report, Inflammatory Bowel Disease (IBD) in Pregnancy Clinical Care Pathway, was published online Jan. 15 in Gastroenterology.
Gender Gap Seen in Accessing Alcohol Treatment With Cirrhosis
MONDAY, Jan. 28, 2019 (HealthDay News) — Women with alcohol-associated cirrhosis (AC) are less likely to receive alcohol use disorder (AUD) treatment than men with the disease even though such treatment is associated with improved outcomes at one year, according to a study published online Jan. 22 in Alcoholism: Clinical & Experimental Research.
Direct-Acting Antivirals Not Tied to Liver Cancer Recurrence
FRIDAY, Jan. 25, 2019 (HealthDay News) — Direct-acting antiviral (DAA) therapy is not associated with increased overall or early hepatocellular carcinoma (HCC) recurrence among patients with a previous complete response to HCC treatment, according to a study published online Jan. 17 in Gastroenterology.
Assay Aids Anticoagulant Dosing of Obese Patients for Bariatric Sx
FRIDAY, Jan. 25, 2019 (HealthDay News) — Endogenous thrombin potential (ETP) may provide better information than anti-factor Xa (anti-XA) in determining the best dosage for blood thinners among obese patients undergoing bariatric surgery, according to a study recently published in Surgery for Obesity and Related Disorders.
Report IDs Areas Lacking Good Practice in Health Tech Assessment
FRIDAY, Jan. 25, 2019 (HealthDay News) — In a report published in the January issue of Value in Health, an ISPOR–The Professional Society for Health Economics and Outcomes Research working group indicates the lack of good practices in three areas of health technology assessment (HTA).